文献速递乳腺癌

MONALEESA-2 研究更新结果:一线 ribociclib 联合来曲唑治疗 HR+/HER2- 晚期乳腺癌

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

MONALEESA-2 III 期研究纳入 668 例绝经后 HR+/HER2- 复发/转移性乳腺癌患者,随机接受 ribociclib 联合来曲唑或安慰剂联合来曲唑。更新分析显示联合组中位 PFS 为 25.3 个月,对照组为 16.0 个月(HR 0.568,95%CI 0.457-0.704,P=9.63×10^-8),总生存数据尚不成熟,安全性可控。

要点

  • 一线 ribociclib 联合来曲唑较单药来曲唑显著延长 PFS(25.3 vs 16.0 个月)。
  • PFS 获益不受 PIK3CA、TP53 突变状态及 Rb、Ki67、p16 表达等影响。
  • 总生存数据尚不成熟,安全性特征与首次分析一致,无新发毒性。

核心结论

  • 更长时间随访后,一线 ribociclib 联合来曲唑相比来曲唑单药在 HR+/HER2- 晚期乳腺癌中维持改善的疗效结局和可控的耐受性。

研究设计与样本

  • III 期 MONALEESA-2 研究,纳入 668 例绝经后 HR+/HER2- 复发/转移性乳腺癌患者,按 1:1 随机分组,按有无肝和/或肺转移分层。

主要发现

  • 第二次中期分析时中位随访 26.4 个月,ribociclib 联合来曲唑组中位 PFS 为 25.3 个月(95%CI 23.0-30.3),安慰剂联合来曲唑组为 16.0 个月(95%CI 13.4-18.2),HR 0.568(95%CI 0.457-0.704),log-rank P=9.63×10^-8。
  • 总生存数据尚不成熟,共观察 116 例死亡(ribociclib 组 50 例,安慰剂组 66 例),HR 0.746(95%CI 0.517-1.078)。
  • 全部治疗患者中 ORR 为 42.5% vs 28.7%,可测量疾病患者中 ORR 为 54.5% vs 38.8%(ribociclib 联合来曲唑 vs 安慰剂联合来曲唑)。
  • Ribociclib 的 PFS 获益不受 PIK3CA 或 TP53 突变状态、总 Rb、Ki67、p16 蛋白表达及 CDKN2A、CCND1、ESR1 mRNA 水平影响;在受体酪氨酸激酶基因野生型患者中获益更明显。

临床怎么用

  • 对于绝经后 HR+/HER2- 晚期乳腺癌患者,一线可考虑 ribociclib(600 mg/day,服药 3 周停 1 周,28 天周期)联合来曲唑(2.5 mg/day 持续)治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. PATIENTS AND METHODS: A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1 : 1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole. The primary end point was locally assessed PFS. The key secondary end point was overall survival (OS). Other secondary end points included overall response rate (ORR) and safety. Biomarker analysis was an exploratory end point. RESULTS: At the time of the second interim analysis, the median duration of follow-up was 26.4 months. Median PFS was 25.3 months [95% confidence interval (CI) 23.0-30.3] for ribociclib plus letrozole and 16.0 months (95% CI 13.4-18.2) for placebo plus letrozole (hazard ratio 0.568; 95% CI 0.457-0.704; log-rank P = 9.63 × 10-8). Ribociclib treatment benefit was maintained irrespective of PIK3CA or TP53 mutation status, total Rb, Ki67, or p16 protein expression, and CDKN2A, CCND1, or ESR1 mRNA levels. Ribociclib benefit was more pronounced in patients with wild-type versus altered receptor tyrosine kinase genes. OS data remain immature, with 116 deaths observed; 50 in the ribociclib arm and 66 in the placebo arm (hazard ratio 0.746; 95% CI 0.517-1.078). The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respectively, and 54.5% versus 38.8%, respectively, for patients with measurable disease. Safety results, after a further 11.1 months of follow-up, were comparable with those reported at the first analysis, with no new or unexpected toxicities observed, and no evidence of cumulative toxicity. CONCLUSIONS: The improved efficacy outcomes and manageable tolerability observed with first-line ribociclib plus letrozole are maintained with longer follow-up, relative to letrozole monotherapy. CLINICAL TRIALS NUMBER: NCT01958021.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018. PMID: 29718092. doi:10.1093/annonc/mdy155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。